Tucson drug startup launches gastric-cancer trial | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

Tucson drug startup launches gastric-cancer trial


Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.

The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.

The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.

https://www.fapvoice.com/wp-content/uploads/2017/07/tucson.jpg

To improve your experience on this site we use cookies. This includes cookies essential for the basic functionalities of our website, cookies used for analytical purposes and cookies enabling us to provide personalized content. You are free to set your cookie preferences at your will.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close